The effect of hormonal contraceptive use on intramuscular cabotegravir (CAB) pharmacokinetics was evaluated in the framework of the HPTN077 clinical study. Participants received 4-week daily oral cabotegravir lead-in, followed by CAB-LA 800 mg injection every 12 weeks (cohort 1) or 600 mg every 8 weeks (after 4-week initial interval between injections, cohort 2), over 41 weeks. Differences in CAB-LA PK parameters were evaluated against self-reported hormonal contraceptive use. Compared to women reporting no hormonal contraception (n=6), oral contraceptive use (n=18) was associated with lower CAB-LA Cmax but was not associated with differences in other PK parameters. No other hormonal contraceptive type (injectable, implants, and other) was associated with significant differences in CAB-LA PK parameters. Cabotegravir Cmax, AUC and Ctrough decreased by 25%, 19% and 9% with contraceptive use. Although oral contraceptive use was associated with differences in CAB-LA Cmax, no differences were observed in other PK parameters, suggesting that this association is not likely to be clinically significant. However, these data highlight the need for further research exploring potential drug-drug interactions between CAB-LA and hormonal contraceptives.